| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/19/2012 | WO2012007510A1 Compounds for binding and imaging amyloid plaques and their use |
| 01/19/2012 | WO2012007387A1 Low- dose lithium for the treatment of neurodegenerative disorders |
| 01/19/2012 | WO2012007138A1 Isomaltulose for use in enhancing mental performance |
| 01/19/2012 | WO2012007006A1 Triazolo- and pyrazoloquinazoline derivatives as pde10a enzyme inhibitor |
| 01/19/2012 | WO2012006958A1 Amids substituted indazole derivativees as ploy(adp-ribose)polymerase inhibitors |
| 01/19/2012 | WO2012006953A1 Oxazine derivatives and their use in the treatment of neurological disorders |
| 01/19/2012 | WO2012006864A1 Triterpenoid saponin compounds, preparation methods and uses thereof |
| 01/19/2012 | WO2012006760A1 Tricyclic compounds as allosteric modulators of metabotropic glutamate receptors |
| 01/19/2012 | WO2012006683A1 Pharmaceutical compositions for sustained delivery of benzodiazepine antagonists |
| 01/19/2012 | WO2011137319A3 Stabilized fibronectin domain compositions, methods and uses |
| 01/19/2012 | WO2011132051A3 Tricycle compounds as phosphodiesterase-10 inhibitors |
| 01/19/2012 | WO2011131896A3 Peptide derivatives, preparation thereof and uses thereof as vectors |
| 01/19/2012 | WO2011127088A3 Methods and compositions for decreasing chronic pain |
| 01/19/2012 | WO2011126910A3 Compositions and methods for the treatment of somatosensory disorders |
| 01/19/2012 | WO2011112873A3 Extracorporeal immunoadsorption treatment |
| 01/19/2012 | WO2011112859A3 Methods relating to olanzapine pharmacogenetics |
| 01/19/2012 | WO2011109494A3 A method for inhibiting alternative pathway mediated disorders with anti-properdin antibodies that inhibit c5 interactions with properdin |
| 01/19/2012 | WO2011109398A3 Methods and compositions for treatment of angelman syndrome and autism spectrum disorders |
| 01/19/2012 | WO2011106424A3 Feline stimulant and method of manufacture |
| 01/19/2012 | US20120016123 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
| 01/19/2012 | US20120016037 Method for prevention and treatment of Alzheimers |
| 01/19/2012 | US20120016036 Material and methods for treating developmental disorders including comorbid and idiopathic autism |
| 01/19/2012 | US20120016020 Solid dispersion of alpha-ketoamide derivatives |
| 01/19/2012 | US20120016016 Methods and compositions for treating complications of diabetes and vascular diseases using flavones |
| 01/19/2012 | US20120016005 Phagocytic cell delivery of rnai |
| 01/19/2012 | US20120016001 Succinimide derivatives as ocular hypotensive agents |
| 01/19/2012 | US20120015992 Napthalene-Based Inhibitors of Anti-Apoptotic Proteins |
| 01/19/2012 | US20120015988 Sulfone Compounds Which Modulate The CB2 Receptor |
| 01/19/2012 | US20120015985 Methods of Administering Pirfenidone Therapy |
| 01/19/2012 | US20120015984 Granulate Formulation of Pirfenidone and Pharmaceutically Acceptable Excipients |
| 01/19/2012 | US20120015983 Synthesis and Novel Salt Forms of (R)-3-((E)-pyrrolidin-3-yl)vinyl)-5-tetrahydropyran-4-yloxy)pyridine |
| 01/19/2012 | US20120015982 Thiazolidinedione analogues |
| 01/19/2012 | US20120015979 Compounds for Modulating TRPV3 Function |
| 01/19/2012 | US20120015977 Quinolinone derivatives useful for the treatment of cns disorders |
| 01/19/2012 | US20120015976 Autotaxin inhibitors |
| 01/19/2012 | US20120015967 Pyrimidine and pyridine derivatives as posh and posh-ap inhibitors |
| 01/19/2012 | US20120015966 Ppar active compounds |
| 01/19/2012 | US20120015961 Isothiourea derivatives or isourea derivatives having bace1 inhibitory activity |
| 01/19/2012 | US20120015957 Piperazinyl derivatives useful as modulators of the neuropeptide y2 receptor |
| 01/19/2012 | US20120015954 Therapeutic agents useful for treating pain |
| 01/19/2012 | US20120015951 Polymorphs of Brimonidine Pamoate |
| 01/19/2012 | US20120015950 Carbamate derivatives of alkyl-heterocycles, preparation thereof and therapeutic use thereof |
| 01/19/2012 | US20120015947 Cyclic hydroxylamine as psychoactive compounds |
| 01/19/2012 | US20120015945 Use of cb1 antagonists and/or inverse agonists for the preparation of drugs that increase motor neuron excitability |
| 01/19/2012 | US20120015944 Tetrazole-substituted arylamides as p2x3 and p2x2/3 antagonists |
| 01/19/2012 | US20120015939 Topical treatment of neuropathic pain and methods of diagnosis |
| 01/19/2012 | US20120015937 Kinase Inhibitors And Their Uses |
| 01/19/2012 | US20120015936 Substituted tetrahydronaphthalenes, method for the production thereof, and use thereof as drugs |
| 01/19/2012 | US20120015933 Spirocyclic nitriles as protease inhibitors |
| 01/19/2012 | US20120015931 Purine compounds selective for pi3k p110 delta, and methods of use |
| 01/19/2012 | US20120015930 Substituted imidazoheterocycle derivatives |
| 01/19/2012 | US20120015929 Novel compounds as cannabinoid receptor ligands |
| 01/19/2012 | US20120015928 Amido Compounds And Their Use As Pharmaceuticals |
| 01/19/2012 | US20120015926 Compounds for the treatment of inflammatory disorders |
| 01/19/2012 | US20120015920 Heterobicyclic metalloprotease inhibitors |
| 01/19/2012 | US20120015915 Formulations of 14-epi-analogues of vitamin d |
| 01/19/2012 | US20120015914 Formulations of 14-epi-analogues of vitamin d |
| 01/19/2012 | US20120015911 Method and compositions for treating amyloid-related diseases |
| 01/19/2012 | US20120015909 Mao-b inhibitors useful for treating obesity |
| 01/19/2012 | US20120015901 Methods and preparations for protecting critically ill patients |
| 01/19/2012 | US20120015891 Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof |
| 01/19/2012 | US20120015885 COMPOSITIONS AND METHODS FOR CaMKII INHIBITORS AND USES THEREOF |
| 01/19/2012 | US20120015884 Polypeptides for Specific Targeting to Otx2 Target Cells |
| 01/19/2012 | US20120015883 Peptoid and synthetic oligomers, pharmaceutical compositions and methods of using same |
| 01/19/2012 | US20120015882 Composition for regulating autonomic nervous activity and method for regulating autonomic nerve |
| 01/19/2012 | US20120015878 Use of adnf polypeptides for treating anxiety and depression |
| 01/19/2012 | US20120015876 Conjugates of glp-1 agonists and uses thereof |
| 01/19/2012 | US20120015868 Metastin derivatives and use thereof |
| 01/19/2012 | US20120015059 Composition for Prevention or Treatment of Insomnia |
| 01/19/2012 | US20120015058 Perfume and cosmetic composition with anti-stress and relaxing effect |
| 01/19/2012 | US20120015052 P2x3 receptor antagonists for treatment of pain |
| 01/19/2012 | US20120015038 Enterically coated cysteamine, cystamine and derivatives thereof |
| 01/19/2012 | US20120015031 Novel gastro-retentive dosage forms |
| 01/19/2012 | US20120015030 Modified release formulations containing drug-ion exchange resin complexes |
| 01/19/2012 | US20120015029 Direct compression formulation and process |
| 01/19/2012 | US20120015024 Methods for treating tweak-related conditions |
| 01/19/2012 | US20120015007 Abuse resistant formula |
| 01/19/2012 | US20120014998 Modified chaperonin 10 |
| 01/19/2012 | US20120014989 PYRROLO[2,3-b]PYRIDIN-4-YL-AMINES AND PYRROLO[2,3-b]PYRIMIDIN-5-YL-AMINES AS JANUS KINASE INHIBITORS |
| 01/19/2012 | US20120014987 Dna vaccine for alzheimer's disease |
| 01/19/2012 | US20120014979 Use of bcl6 inhibitors for treating autoimmune diseases |
| 01/19/2012 | US20120014974 Methods of modulating cell death based on the bit1/aes regulatory pathway |
| 01/19/2012 | US20120014970 Therapeutic Compositions for Treatment of Corneal Disorders |
| 01/19/2012 | US20120014969 ErbB3 ANTIBODIES |
| 01/19/2012 | US20120014966 Methods for the treatment of il-1beta related conditions |
| 01/19/2012 | US20120014964 Alpha synuclein toxicity |
| 01/19/2012 | US20120014960 Composition Comprising Antibodies to LINGO or Fragments Thereof |
| 01/19/2012 | US20120014950 Antibodies That Specifically Bind to DR3 |
| 01/19/2012 | US20120014946 Prevention and treatment of pain using monoclonal antibodies and antibody fragments to lysophosphatidic acid |
| 01/19/2012 | US20120014944 Prevention and treatment of pain using antibodies to lysophosphatidic acid |
| 01/19/2012 | US20120014937 Human Beta-Adrenergic receptor kinase polypeptide and methods |
| 01/19/2012 | US20120014936 Methods and compositions for cns delivery of heparan n-sulfatase |
| 01/19/2012 | US20120014935 Recombinant human cln2 protein and methods of its production and use |
| 01/19/2012 | US20120014931 Human late stage motor neuron progenitor cells |
| 01/19/2012 | US20120014920 Annexin and its use to treat inflammatory disorders |
| 01/19/2012 | US20120014918 Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as dhodh inhibitors |
| 01/19/2012 | US20120014911 Regulators of the Interferon-Alpha Receptor 1 (IFNAR1) Chain of the Interferon Receptor |
| 01/19/2012 | US20120014880 METHOD FOR THE PREVENTION AND TREATMENT OF ESSENTIAL TREMOR BY REGULATING alpha1G T-TYPE CALCIUM CHANNEL OR BY T-TYPE CALCIUM CHANNEL BLOCKERS |
| 01/19/2012 | CA2807354A1 P2x4 receptor antagonist |
| 01/19/2012 | CA2807318A1 Novel tetrahydropyrazolo[3,4-b]azepine derivatives and their use as allosteric modulators of metabotropic glutamate receptors |